Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in NF2 and NF2-related Tumors
NCT00973739Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 2009
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in neurofibromatosis type 2 (NF2), vestibular schwannoma (VS), sponsored by NYU Langone Health. Started Sep 2009; status: completed.
02
Drugs
lapatinib
03
Conditions
neurofibromatosis type 2 (NF2)vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT00973739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00973739.